Targeting Nrf2 signaling improves bacterial clearance by alveolar macrophages in patients with COPD and in a mouse model.
Identifieur interne : 001508 ( Main/Curation ); précédent : 001507; suivant : 001509Targeting Nrf2 signaling improves bacterial clearance by alveolar macrophages in patients with COPD and in a mouse model.
Auteurs : Christopher J. Harvey [États-Unis] ; Rajesh K. Thimmulappa ; Sanjay Sethi ; Xiaoni Kong ; Lonny Yarmus ; Robert H. Brown ; David Feller-Kopman ; Robert Wise ; Shyam BiswalSource :
- Science translational medicine [ 1946-6242 ] ; 2011.
Descripteurs français
- KwdFr :
- Adulte d'âge moyen, Animaux, Broncho-pneumopathie chronique obstructive (génétique), Broncho-pneumopathie chronique obstructive (microbiologie), Broncho-pneumopathie chronique obstructive (métabolisme), Cellules cultivées, Facteur-2 apparenté à NF-E2 (génétique), Facteur-2 apparenté à NF-E2 (métabolisme), Femelle, Haemophilus influenzae (pathogénicité), Humains, Isothiocyanates, Macrophages alvéolaires (), Macrophages alvéolaires (microbiologie), Macrophages alvéolaires (métabolisme), Mâle, Phagocytose (), Pseudomonas aeruginosa (pathogénicité), Récepteurs immunologiques (métabolisme), Souris, Sujet âgé, Thiocyanates (usage thérapeutique).
- MESH :
- génétique : Broncho-pneumopathie chronique obstructive, Facteur-2 apparenté à NF-E2.
- microbiologie : Broncho-pneumopathie chronique obstructive, Macrophages alvéolaires.
- métabolisme : Broncho-pneumopathie chronique obstructive, Facteur-2 apparenté à NF-E2, Macrophages alvéolaires, Récepteurs immunologiques.
- pathogénicité : Haemophilus influenzae, Pseudomonas aeruginosa.
- usage thérapeutique : Thiocyanates.
- Adulte d'âge moyen, Animaux, Cellules cultivées, Femelle, Humains, Isothiocyanates, Macrophages alvéolaires, Mâle, Phagocytose, Souris, Sujet âgé.
English descriptors
- KwdEn :
- Aged, Animals, Cells, Cultured, Female, Haemophilus influenzae (pathogenicity), Humans, Isothiocyanates, Macrophages, Alveolar (drug effects), Macrophages, Alveolar (metabolism), Macrophages, Alveolar (microbiology), Male, Mice, Middle Aged, NF-E2-Related Factor 2 (genetics), NF-E2-Related Factor 2 (metabolism), Phagocytosis (drug effects), Pseudomonas aeruginosa (pathogenicity), Pulmonary Disease, Chronic Obstructive (genetics), Pulmonary Disease, Chronic Obstructive (metabolism), Pulmonary Disease, Chronic Obstructive (microbiology), Receptors, Immunologic (metabolism), Thiocyanates (therapeutic use).
- MESH :
- chemical , genetics : NF-E2-Related Factor 2.
- chemical , metabolism : NF-E2-Related Factor 2, Receptors, Immunologic.
- chemical , therapeutic use : Thiocyanates.
- chemical : Isothiocyanates.
- drug effects : Macrophages, Alveolar, Phagocytosis.
- genetics : Pulmonary Disease, Chronic Obstructive.
- metabolism : Macrophages, Alveolar, Pulmonary Disease, Chronic Obstructive.
- microbiology : Macrophages, Alveolar, Pulmonary Disease, Chronic Obstructive.
- pathogenicity : Haemophilus influenzae, Pseudomonas aeruginosa.
- Aged, Animals, Cells, Cultured, Female, Humans, Male, Mice, Middle Aged.
Abstract
Patients with chronic obstructive pulmonary disease (COPD) have innate immune dysfunction in the lung largely due to defective macrophage phagocytosis. This deficiency results in periodic bacterial infections that cause acute exacerbations of COPD, a major source of morbidity and mortality. Recent studies indicate that a decrease in Nrf2 (nuclear erythroid-related factor 2) signaling in patients with COPD may hamper their ability to defend against oxidative stress, although the role of Nrf2 in COPD exacerbations has not been determined. Here, we test whether activation of Nrf2 by the phytochemical sulforaphane restores phagocytosis of clinical isolates of nontypeable Haemophilus influenza (NTHI) and Pseudomonas aeruginosa (PA) by alveolar macrophages from patients with COPD. Sulforaphane treatment restored bacteria recognition and phagocytosis in alveolar macrophages from COPD patients. Furthermore, sulforaphane treatment enhanced pulmonary bacterial clearance by alveolar macrophages and reduced inflammation in wild-type mice but not in Nrf2-deficient mice exposed to cigarette smoke for 6 months. Gene expression and promoter analysis revealed that Nrf2 increased phagocytic ability of macrophages by direct transcriptional up-regulation of the scavenger receptor MARCO. Disruption of Nrf2 or MARCO abrogated sulforaphane-mediated bacterial phagocytosis by COPD alveolar macrophages. Our findings demonstrate the importance of Nrf2 and its downstream target MARCO in improving antibacterial defenses and provide a rationale for targeting this pathway, via pharmacological agents such as sulforaphane, to prevent exacerbations of COPD caused by bacterial infection.
DOI: 10.1126/scitranslmed.3002042
PubMed: 21490276
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000638
- to stream PubMed, to step Curation: Pour aller vers cette notice dans l'étape Curation :000636
- to stream PubMed, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :000600
- to stream Ncbi, to step Merge: Pour aller vers cette notice dans l'étape Curation :000445
- to stream Ncbi, to step Curation: Pour aller vers cette notice dans l'étape Curation :000445
- to stream Ncbi, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :000445
- to stream Main, to step Merge: Pour aller vers cette notice dans l'étape Curation :001510
Links to Exploration step
pubmed:21490276Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Targeting Nrf2 signaling improves bacterial clearance by alveolar macrophages in patients with COPD and in a mouse model.</title><author><name sortKey="Harvey, Christopher J" sort="Harvey, Christopher J" uniqKey="Harvey C" first="Christopher J" last="Harvey">Christopher J. Harvey</name><affiliation wicri:level="2"><nlm:affiliation>Department of Environmental Health Sciences, Johns Hopkins University, Baltimore, MD 21205, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Environmental Health Sciences, Johns Hopkins University, Baltimore, MD 21205</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Thimmulappa, Rajesh K" sort="Thimmulappa, Rajesh K" uniqKey="Thimmulappa R" first="Rajesh K" last="Thimmulappa">Rajesh K. Thimmulappa</name></author><author><name sortKey="Sethi, Sanjay" sort="Sethi, Sanjay" uniqKey="Sethi S" first="Sanjay" last="Sethi">Sanjay Sethi</name></author><author><name sortKey="Kong, Xiaoni" sort="Kong, Xiaoni" uniqKey="Kong X" first="Xiaoni" last="Kong">Xiaoni Kong</name></author><author><name sortKey="Yarmus, Lonny" sort="Yarmus, Lonny" uniqKey="Yarmus L" first="Lonny" last="Yarmus">Lonny Yarmus</name></author><author><name sortKey="Brown, Robert H" sort="Brown, Robert H" uniqKey="Brown R" first="Robert H" last="Brown">Robert H. Brown</name></author><author><name sortKey="Feller Kopman, David" sort="Feller Kopman, David" uniqKey="Feller Kopman D" first="David" last="Feller-Kopman">David Feller-Kopman</name></author><author><name sortKey="Wise, Robert" sort="Wise, Robert" uniqKey="Wise R" first="Robert" last="Wise">Robert Wise</name></author><author><name sortKey="Biswal, Shyam" sort="Biswal, Shyam" uniqKey="Biswal S" first="Shyam" last="Biswal">Shyam Biswal</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2011">2011</date><idno type="RBID">pubmed:21490276</idno><idno type="pmid">21490276</idno><idno type="doi">10.1126/scitranslmed.3002042</idno><idno type="wicri:Area/PubMed/Corpus">000638</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000638</idno><idno type="wicri:Area/PubMed/Curation">000636</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000636</idno><idno type="wicri:Area/PubMed/Checkpoint">000600</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000600</idno><idno type="wicri:Area/Ncbi/Merge">000445</idno><idno type="wicri:Area/Ncbi/Curation">000445</idno><idno type="wicri:Area/Ncbi/Checkpoint">000445</idno><idno type="wicri:Area/Main/Merge">001510</idno><idno type="wicri:Area/Main/Curation">001508</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Targeting Nrf2 signaling improves bacterial clearance by alveolar macrophages in patients with COPD and in a mouse model.</title><author><name sortKey="Harvey, Christopher J" sort="Harvey, Christopher J" uniqKey="Harvey C" first="Christopher J" last="Harvey">Christopher J. Harvey</name><affiliation wicri:level="2"><nlm:affiliation>Department of Environmental Health Sciences, Johns Hopkins University, Baltimore, MD 21205, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Environmental Health Sciences, Johns Hopkins University, Baltimore, MD 21205</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Thimmulappa, Rajesh K" sort="Thimmulappa, Rajesh K" uniqKey="Thimmulappa R" first="Rajesh K" last="Thimmulappa">Rajesh K. Thimmulappa</name></author><author><name sortKey="Sethi, Sanjay" sort="Sethi, Sanjay" uniqKey="Sethi S" first="Sanjay" last="Sethi">Sanjay Sethi</name></author><author><name sortKey="Kong, Xiaoni" sort="Kong, Xiaoni" uniqKey="Kong X" first="Xiaoni" last="Kong">Xiaoni Kong</name></author><author><name sortKey="Yarmus, Lonny" sort="Yarmus, Lonny" uniqKey="Yarmus L" first="Lonny" last="Yarmus">Lonny Yarmus</name></author><author><name sortKey="Brown, Robert H" sort="Brown, Robert H" uniqKey="Brown R" first="Robert H" last="Brown">Robert H. Brown</name></author><author><name sortKey="Feller Kopman, David" sort="Feller Kopman, David" uniqKey="Feller Kopman D" first="David" last="Feller-Kopman">David Feller-Kopman</name></author><author><name sortKey="Wise, Robert" sort="Wise, Robert" uniqKey="Wise R" first="Robert" last="Wise">Robert Wise</name></author><author><name sortKey="Biswal, Shyam" sort="Biswal, Shyam" uniqKey="Biswal S" first="Shyam" last="Biswal">Shyam Biswal</name></author></analytic><series><title level="j">Science translational medicine</title><idno type="eISSN">1946-6242</idno><imprint><date when="2011" type="published">2011</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Animals</term><term>Cells, Cultured</term><term>Female</term><term>Haemophilus influenzae (pathogenicity)</term><term>Humans</term><term>Isothiocyanates</term><term>Macrophages, Alveolar (drug effects)</term><term>Macrophages, Alveolar (metabolism)</term><term>Macrophages, Alveolar (microbiology)</term><term>Male</term><term>Mice</term><term>Middle Aged</term><term>NF-E2-Related Factor 2 (genetics)</term><term>NF-E2-Related Factor 2 (metabolism)</term><term>Phagocytosis (drug effects)</term><term>Pseudomonas aeruginosa (pathogenicity)</term><term>Pulmonary Disease, Chronic Obstructive (genetics)</term><term>Pulmonary Disease, Chronic Obstructive (metabolism)</term><term>Pulmonary Disease, Chronic Obstructive (microbiology)</term><term>Receptors, Immunologic (metabolism)</term><term>Thiocyanates (therapeutic use)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte d'âge moyen</term><term>Animaux</term><term>Broncho-pneumopathie chronique obstructive (génétique)</term><term>Broncho-pneumopathie chronique obstructive (microbiologie)</term><term>Broncho-pneumopathie chronique obstructive (métabolisme)</term><term>Cellules cultivées</term><term>Facteur-2 apparenté à NF-E2 (génétique)</term><term>Facteur-2 apparenté à NF-E2 (métabolisme)</term><term>Femelle</term><term>Haemophilus influenzae (pathogénicité)</term><term>Humains</term><term>Isothiocyanates</term><term>Macrophages alvéolaires ()</term><term>Macrophages alvéolaires (microbiologie)</term><term>Macrophages alvéolaires (métabolisme)</term><term>Mâle</term><term>Phagocytose ()</term><term>Pseudomonas aeruginosa (pathogénicité)</term><term>Récepteurs immunologiques (métabolisme)</term><term>Souris</term><term>Sujet âgé</term><term>Thiocyanates (usage thérapeutique)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>NF-E2-Related Factor 2</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>NF-E2-Related Factor 2</term><term>Receptors, Immunologic</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Thiocyanates</term></keywords><keywords scheme="MESH" type="chemical" xml:lang="en"><term>Isothiocyanates</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Macrophages, Alveolar</term><term>Phagocytosis</term></keywords><keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Pulmonary Disease, Chronic Obstructive</term></keywords><keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Broncho-pneumopathie chronique obstructive</term><term>Facteur-2 apparenté à NF-E2</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Macrophages, Alveolar</term><term>Pulmonary Disease, Chronic Obstructive</term></keywords><keywords scheme="MESH" qualifier="microbiologie" xml:lang="fr"><term>Broncho-pneumopathie chronique obstructive</term><term>Macrophages alvéolaires</term></keywords><keywords scheme="MESH" qualifier="microbiology" xml:lang="en"><term>Macrophages, Alveolar</term><term>Pulmonary Disease, Chronic Obstructive</term></keywords><keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Broncho-pneumopathie chronique obstructive</term><term>Facteur-2 apparenté à NF-E2</term><term>Macrophages alvéolaires</term><term>Récepteurs immunologiques</term></keywords><keywords scheme="MESH" qualifier="pathogenicity" xml:lang="en"><term>Haemophilus influenzae</term><term>Pseudomonas aeruginosa</term></keywords><keywords scheme="MESH" qualifier="pathogénicité" xml:lang="fr"><term>Haemophilus influenzae</term><term>Pseudomonas aeruginosa</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Thiocyanates</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Animals</term><term>Cells, Cultured</term><term>Female</term><term>Humans</term><term>Male</term><term>Mice</term><term>Middle Aged</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte d'âge moyen</term><term>Animaux</term><term>Cellules cultivées</term><term>Femelle</term><term>Humains</term><term>Isothiocyanates</term><term>Macrophages alvéolaires</term><term>Mâle</term><term>Phagocytose</term><term>Souris</term><term>Sujet âgé</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Patients with chronic obstructive pulmonary disease (COPD) have innate immune dysfunction in the lung largely due to defective macrophage phagocytosis. This deficiency results in periodic bacterial infections that cause acute exacerbations of COPD, a major source of morbidity and mortality. Recent studies indicate that a decrease in Nrf2 (nuclear erythroid-related factor 2) signaling in patients with COPD may hamper their ability to defend against oxidative stress, although the role of Nrf2 in COPD exacerbations has not been determined. Here, we test whether activation of Nrf2 by the phytochemical sulforaphane restores phagocytosis of clinical isolates of nontypeable Haemophilus influenza (NTHI) and Pseudomonas aeruginosa (PA) by alveolar macrophages from patients with COPD. Sulforaphane treatment restored bacteria recognition and phagocytosis in alveolar macrophages from COPD patients. Furthermore, sulforaphane treatment enhanced pulmonary bacterial clearance by alveolar macrophages and reduced inflammation in wild-type mice but not in Nrf2-deficient mice exposed to cigarette smoke for 6 months. Gene expression and promoter analysis revealed that Nrf2 increased phagocytic ability of macrophages by direct transcriptional up-regulation of the scavenger receptor MARCO. Disruption of Nrf2 or MARCO abrogated sulforaphane-mediated bacterial phagocytosis by COPD alveolar macrophages. Our findings demonstrate the importance of Nrf2 and its downstream target MARCO in improving antibacterial defenses and provide a rationale for targeting this pathway, via pharmacological agents such as sulforaphane, to prevent exacerbations of COPD caused by bacterial infection.</div></front></TEI></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/StressCovidV1/Data/Main/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001508 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Curation/biblio.hfd -nk 001508 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= StressCovidV1
|flux= Main
|étape= Curation
|type= RBID
|clé= pubmed:21490276
|texte= Targeting Nrf2 signaling improves bacterial clearance by alveolar macrophages in patients with COPD and in a mouse model.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Curation/RBID.i -Sk "pubmed:21490276" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Curation/biblio.hfd \
| NlmPubMed2Wicri -a StressCovidV1
| This area was generated with Dilib version V0.6.33. |  |